Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

PURPOSE: Dolutegravir (DTG), an unboosted HIV integrase inhibitor (INI), is metabolized by UGT1A1 and to a minor extent by CYP3A. Renal elimination of unchanged DTG is very low (< 1 %). As renal impairment may affect pharmacokinetics (PK), even for drugs primarily metabolized or secreted in bile,...

Descripción completa

Detalles Bibliográficos
Autores principales: Weller, Stephen, Borland, Julie, Chen, Shuguang, Johnson, Mark, Savina, Paul, Wynne, Brian, Wajima, Toshihiro, Peppercorn, Amanda F., Piscitelli, Stephen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889630/
https://www.ncbi.nlm.nih.gov/pubmed/24096683
http://dx.doi.org/10.1007/s00228-013-1590-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889630/
https://www.ncbi.nlm.nih.gov/pubmed/24096683
http://dx.doi.org/10.1007/s00228-013-1590-9

Ejemplares similares